Zydus gains final FDA nod for Sacubitril and Valsartan Tablets

hanuman

Active member
us-fda-approval-1.jpg


Zydus Lifesciences has received final approval from the United States Food and Drug Administration to market Sacubitril and Valsartan Tablets, 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg (USRLD: Entresto tablets).

Sacubitril and Valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation. The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad.

Sacubitril and Valsartan tablets had annual sales of USD 5,483 mn in the United States (IQVIA MAT May 2024). The group now has 399 approvals and has so far filed over 460 ANDAs (as of March 2024) since the commencement of the filing process in FY 2003-04.

The post appeared first on .
 
Top
AdBlock Detected

We get it, advertisements are annoying!

Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.

I've Disabled AdBlock